Viridian Therapeutics, Inc. Share Price
NASDAQ: VRDN | Mid CapViridian Therapeutics, Inc. Stock Performance
Viridian Therapeutics, Inc. Share Price Today
As of 31 October 2026, Viridian Therapeutics, Inc.'s share price is $24.69. The stock opened at $24.80, compared to its previous close of $24.82. During today's trading session, Viridian Therapeutics, Inc.'s share price traded between $24.14 and $25.00, with an average price of $24.57. Over the past 52 weeks, the stock has recorded a high of $34.25 and a low of $13.18. In terms of performance, Viridian Therapeutics, Inc.'s share price has risen by 83.50% over the last six months and is up 4.53% on a year-on-year basis.
Viridian Therapeutics, Inc. Share Price Chart
Viridian Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Viridian Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Viridian Therapeutics, Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $20.45 | $24.71 | +19.92% |
Sep 2026 | $23.19 | $20.61 | -13.75% |
Aug 2026 | $18.68 | $23.89 | +26.20% |
Jul 2026 | $18.95 | $18.93 | +2.94% |
Jun 2026 | $17.54 | $18.39 | +4.34% |
May 2026 | $13.58 | $17.63 | +30.99% |
Apr 2026 | $19.72 | $13.46 | -31.16% |
Mar 2026 | $28.76 | $19.55 | -33.41% |
Feb 2026 | $33.23 | $29.35 | -11.07% |
Jan 2026 | $31.23 | $33.01 | +6.02% |
Dec 2025 | $31.91 | $31.13 | -2.57% |
Nov 2025 | $23.78 | $31.95 | +35.27% |